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Abstract
Malaria causes hundreds of thousands of human deaths every year, and the World
Health Assembly has made it a priority. To help eliminate this disease, there is a pressing
need  for  the  development  and  implementation  of  new  strategies  to  improve  the
prevention and treatment, due in part to antimalarial drug resistances. This chapter
focuses  on  two  strategies  to  inactivate  the  malaria  parasite  in  blood,  which  are
photodynamic therapy (PDT) and inhibition of hemozoin formation. The PDT strategy
permits  either  a  control  of  the  proliferation  of  mosquito  larvae  to  develop  some
photolarvicides for the prevention or a photoinactivation of the malaria parasite in red
blood cells (RBCs) to minimize infection transmission by transfusion. The inhibition of
hemozoin formation strategy is used for the development of new antimalarial drug by
understanding its formation mechanism.
Keywords: hemozoin, photodynamic therapy, blood decontamination, heme-drug in-
teraction, preventive treatment, curative treatment
1. Introduction
Malaria in humans is an infectious disease caused by parasites of the genus Plasmodium, and
it is spread to humans by the bite of the female anopheles mosquito. Among the species of
Plasmodium, five are capable of inducing human disease. These are the species: falciparum,
vivax, malariae, ovale, and knowlesi. The first is the most widespread and the most virulent,
which is responsible of 80% of infections and about 90% of deaths, especially in Africa.
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In 2000, malaria was seen as one of the most critical constraints on global development and
considered as a priority challenge of the “Millennium Development Goals” (MDGs). The main
objective was to halt and begin to reverse the incidence of malaria by 2015 (Target 6C). The
World Malaria Report 2015 written by the World Health Organization (WHO) summarizes
advances that have taken place in each WHO region over the 2000–2015 period [1]. Malaria is
endemic in 95 countries mainly in Africa (88%). This report shows that this goal was achieved
with an almost 37% and 60% drop in malaria incidence and in death rates, respectively, over
this period. In 2015, 214 million cases of malaria were recorded including 438 000 that have led
to the death of the patients, reflecting a decline of 18% and 48% in cases and deaths, respectively,
over the 2000–2015 period. In May 2015, the Global Technical Strategy for Malaria 2016–2030 was
endorsed by the World Health Assembly. This strategy has its goal to reach a 90% reduction
in global malaria incidence and mortality by 2030.
With regard to preventing malaria in countries at risk, the WHO recommends sleeping under
an insecticide-treated mosquito net (ITN) and protecting by indoor residual spraying (IRS).
Furthermore, the recommended treatment is an artemisinin-based combination therapy
(ACT).
Despite a slight decrease, this disease remains a leading cause of death of children in Africa
due in part to antimalarial drug resistances. Declines in cases and deaths caused by malaria
are due to the development of new strategies such as the use of photodynamic therapy (PDT)
for the control of the infection vector or to induce inactivation of Plasmodium falciparum and
targeting the hemozoin inhibition, with the aim of preventing and treating malaria.
2. Inhibition of hemozoin formation
2.1. Generalities on the hemozoin production by P. falciparum
Hemoglobin, the main component of red blood cells (RBCs), represents almost 95% of the
protein part of the cytosol (liquid fraction of the cell cytoplasm) up to reach 5 mM concentration
in the cytoplasm (>300 mg/mL) [2]. Hemoglobin essential for cellular respiration is composed
of a protein portion (globin) and a complex molecular structure centered on an iron atom
(heme, ferriprotoporphyrin IX, Fe(II)PPIX which carries oxygen, and carbon dioxide from
breathing).
During its life cycle in the red blood cell (RBC), the human malaria parasite (Figure 1), P.
falciparum, gobbles up between 60 and 80% of hemoglobin from the host cell cytoplasm [3] by
using a cytostome (cell mouth) for the purpose of transporting it to its acidic digestive food
vacuole (pH ≈ 5.0–5.4 [4, 5]). At this acidic pH maintained by means of an ATPase pump
enabling activation of a proton gradient, the hemoglobin is degraded into amino acids that are
used for the production of parasite proteins, thereby allowing the release of free heme which
is toxic to the parasite [6–9]. The hemoglobin degradation mechanism was studied in detail,
and it was shown that it implies enzymes (proteases) present in the food vacuole of the parasite
such as two aspartic (plasmepsins I and II) and cysteine (falcipain) proteases [10–14].
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The heme detoxification is a crucial step for the survival and growth of the parasite [15]. Heme
is assumed to generate the formation of reactive oxygen species (ROS), via the Fenton reaction
catalyzed by its iron atom [16–18], and hydroxyl radicals that may lead to peroxidation of lipid
membranes [19–21]. It was postulated also that specific heme-H2O2 reaction might produce
free radicals [21] which may result in oxidation of lipids, proteins, and DNA [22, 23].
Figure 1. Hemoglobin degradation by Plasmodium falciparum in RBC.
The detoxification of heme begins with the self-oxidation of the Fe(II) in heme group into Fe(III)
to form potentially toxic hydroxyferriprotoporphyrin IX (hematin, HO-Fe(III)PPIX; Figure 2)
[8, 24, 25]. This detoxification ends with the formation of highly insoluble brown crystals
known as hemozoin (malaria pigment; Figure 2) [26, 27] according to biomineralization or
biocrystallization processes [28, 29] and not via a polymerization as previously believed; the
x-ray structure is identical to a synthetic Fe(III)PPIX compound called β-hematin [30]. In 2000,
the crystalline structure of β-hematin was determined to be a cyclic dimer of Fe(III)PPIX,
involving two coordination bonds between the propionate side chain of one and the Fe(III)
atom of the other [28]. These cyclic dimers are self-assembled in the crystal lattice via inter-
molecular hydrogen bonds which link the propionic acid side chains of each Fe(III)PPIX,
thereby losing their toxic potential (heme detoxification), and then eliminated from the food
vacuole. In 2010, the crystal structure of P. falciparum hemozoin has been solved by Klonis et
al. after a reanalysis of x-ray crystallographic data for β-hematin [31].
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Figure 2. Chemical structure of heme, hematin, and hemozoin.
The mechanism concerning formation of β-hematin (hemozoin) in vivo and in vitro is still
ambiguous and will be discussed in the following section.
2.2. Mechanistic assumptions about the hemozoin formation
The heme detoxification by P. falciparum results in the formation of hemozoin by template-
mediated crystallization (“biocrystallization”), and a number of studies have been conducted
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in order to understand the hemozoin formation. Hemozoin or β‐hematin (synthetic hemozoin)
was used for these studies, and various mechanisms about the β‐hematin formation have been
postulated for the in vivo process.
Before beginning the discussion about mechanistic assumptions of the hemozoin formation,
it is worth noting that when comparing the natural hemozoin and its synthetic version (β‐
hematin), we see a considerable difference in their size and shape. The natural hemozoin
consists of small crystals ranging in size from 50 to 500 nm, whereas for the synthetic β‐hematin,
these crystals are bigger (50 nm to 20 μm) and depend on solvent used for the recrystallization.
This difference in size can lead to diverse immunomodulatory responses [32].
The various studies of this mechanism gave rise to a number of assumptions [11, 33, 34] such
as spontaneous [35, 36], autocatalyzed [37, 38], enzyme‐catalyzed [39], lipid‐catalyzed [40–
43], and initiated or catalyzed by histidine‐rich proteins (HRPs) [44–48], which can be divided
into two main types: non‐biological and biological conditions (Figure 3).
Figure 3. Postulated mechanisms about the hemozoin formation by Plasmodium falciparum.
The first category (non‐biological conditions) is based on the assumption that β‐hematin
formation can happen spontaneously without any external help [35]. This observation comes
from studies conducted in acetate solution, which shows that the β‐hematin can be formed at
a moderate low pH compared to the acidic digestive food vacuole [36].
The second category includes of all other mechanisms and provides a presumption that the
β‐hematin formation can catalyze itself or requires the presence of biological material (bio‐
crystallization). The first idea about an autocatalytic process is, among other things, due to a
recent observation of the continued growth of a preexisting hemozoin crystal [37].
As regards the second idea, it began in 1992 with the work of Slater and Cerami [39] which
have shown that heme can react with trophozoite lysate extracts at pH 5–6 to generate
hemozoin and that chloroquine, an antimalarial drug, can inhibit this formation. The authors
concluded that the creation of the two propionate‐Fe(III) linkages during the heme detoxifi‐
cation is catalyzed by an enzyme named heme polymerase. The use of extracts from Plasmodium
berghei (rodent malaria) by Chou and Fitch gave equivalent results [49].
Despite being challenged, this heme polymerase theory attempted to explain hemozoin
propagation without clarifying its initiation. This breach paved the way for other hypotheses
about the formation of hemozoin involving a protein or enzyme [38]. Firstly, Hempelman in
2007 introduced the concept of “biocrystallization” instead of “polymerization” to describe
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the hemozoin formation process [29]. One of the hypotheses suggested that biocrystallization
is caused by enzymes, which postulate the presence of proteins such as histidine-rich proteins
(HRPs). Sullivan and coworkers [48] showed that HRPs I, II, and III, present in the parasite’s
digestive vacuole, may be able to promote the formation of hemozoin in vitro. In 2008, Jani et
al. [46] identified a novel heme detoxification protein (HDP) from P. falciparum, which is
considered as one of the most powerful of the hemozoin-producing enzymes. As an example,
we could cite the work of Choi and coworkers in 2002 and Nakatani et al. in 2014 concerning
the elucidated reaction mechanisms of HRP II and HDP [44, 47]. These authors have shown
that some histidine residues are active sites in these proteins and can bind with heme to
promote the heme dimerization by bringing two molecules. This dimer would be used as a
crystal growth initiator of hemozoin. Recently, Chugh and coworkers have established that
HDP and falcipain-2 can work in tandem within the digestive food vacuole of the parasite to
transform hemoglobin efficiently into hemozoin [45].
Finally, the last proposed mechanism is the biocrystallization catalyzed by lipids [40–43, 50].
These lipids, produced by the parasite after digesting the transport vesicles and trapped in its
food vacuole, have been characterized with spectroscopic studies [7, 41] and known as a neutral
lipid blend (NLB) and monopalmitoylglycerol (MPG). In 2007, Pisciotta et al. proved that
Fe(III)PPIX can be processed into β-hematin through the action of these lipids with the yield
of 80% or more [51] as assumed by Sullivan two years before [27].
The design and development of new antimalarial drugs first begin with the understanding of
the mechanism of action of P. falciparum after invading RBCs and giving rise to hemozoin
formation via the heme detoxification. Although this mechanism is not completely elucidated
and still requires much work, these assumptions allow researchers to develop new strategies
with a view to solving the problem of antimalarial drug resistance concerning chloroquine and
artemisinin, the two most antimalarial drugs used to treat malaria.
By way of example, new strategies envisaged include the use of PDT (Section 3) in order to kill
mosquito larvae (prevention Section 3.2) or to inactivate malaria parasites in the RBCs
(treatment Section 3.3) but also the design of new antimalarial drugs that are able to inhibit
the β-hematin formation by heme-drug interaction (treatment Section 4).
3. Photodynamic therapy for preventive and curative treatments
3.1. Generalities
The therapeutic effects of light are known since ancient times and were widely used in
combination with natural substances for centuries in Chinese, Egyptian, or Indian civilizations
for the treatment of numerous diseases such psoriasis, vitiligo, and rickets [52]. The integration
of the concepts of “phototherapy” and then “photosensitivity” in modern medicine is much
more recent, since it originated in the work of Niels Finsen, a Danish doctor who demonstrated
in the 1890s the positive influence of light on the healing process (Nobel Prize for Medicine in
1903) [53]. However, the concept of exogenous photosensitizer (PS), that is to say, therapeutic
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molecule introduced for the specific purpose of interacting with light to generate the desired
therapeutic effect, was introduced only a few years later, at the turn of the twentieth century
by Raab and von Tappeiner as related by Spikes in a very good historical review [54]. In 1900,
Oscar Raab, a student at the Department of Pharmacology of the University of Munich in the
group of Hermann von Tappeiner, tried to characterize the influence of acridine on the
development of Paramecium caudatum and Plasmodium malariae, a paramecium responsible for
malaria. Very quickly, Raab noted that, according to the hour of the treatment and the weather
conditions, the impact of administered acridine on the survival of microorganisms seemed
extremely variable. He quickly demonstrated that the mechanism of cell death induced by
acridine requires activation by light irradiation. Later, von Tappeiner identified oxygen as the
third component (with the PS and light source) involved in photo-induced mechanism. He
proposed the term “photodynamic therapy” (photodynamische Wirkung in the original) to
define all therapeutic protocols involving these three elements [55]. von Tappeiner’s team
experimented eosin as PS to treat tumors in six patients, and some promising results were
obtained [56]. Unfortunately, in this period, the concept did not arouse reactions on behalf of
the scientific world in Western medicine [57].
In summary, PDT is an innovative medical treatment involving the concomitant action of three
components that are photoactivatable molecule called PS, light of a suitable wavelength, and
oxygen present in the biological medium. After light excitation of the PS and energy transfer
from the excited PS to oxygen, reactive oxygen species are produced especially singlet oxygen
(1O2) that can destroy cancer cells in proximity. It is interesting to notice that the PS itself is
nontoxic and turns out to be toxic only with light. Light is also nontoxic by itself. The selectivity
of action of PDT allows through a localized light radiation to eradicate tumor cells while
preserving healthy cells. PS fluorescence properties are also an asset that is utilized to visualize
the diseased tissue. The mechanisms are summarized in Figure 4.
Figure 4. Mechanism of PDT (simplified Perrin-Jablonski diagram).
This technique was used clinically for many years, and in 1993, bladder cancer Photofrin PDT
receives government approval in Canada. Since then, PDT has been developed in many
countries of the world. PDT is an obvious treatment for dermatology applications, and it is
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used daily for skin diseases such as actinic keratoses, acne, and wine stain [57]. PDT has been
also widely employed as a treatment for age-related macular degeneration (ARMD). However,
since 2006, intravitreal injections of Avastin, humanized monoclonal antibody having anti-
angiogenic activity, significantly reduced the use of PDT to treat ARMD. In urology, the French
company Steba Biotech has invested heavily to develop a new PS, the TOOKAD® (currently
in phase 3) for the treatment of prostate cancer. The first clinical applications demonstrate the
technical feasibility [58]. In gastroenterology, PDT demonstrated its effectiveness for the
treatment of superficial cancers of the esophagus in patients ineligible for further treatment,
with a postradiation recurrence, severe dysplasia in Barrett, and unresectable cholangiocarci-
noma [59]. In gynecology, the interest of PDT has been shown in the treatment of cervical
dysplasia of low- and high-grade cervical lesions [60]. Our team developed folic acid-targeted
photosensitizers that could be very efficient to treat peritoneal carcinosis, and a preclinical
evaluation is under progress [61, 62]. In pulmonology, the number of studies on the treatment
of lung cancer is still limited, and the role of PDT in the therapeutic arsenal of the practitioner
remains to be demonstrated. PDT appears to be a promising treatment for malignant pleural
mesothelioma (MPM). Thus, PDT has been tested in phase I and phase II clinical trials to MPM
patients in combination with extrapleural pneumonectomy or pleurectomy/decortication and
an intravenous chemotherapy. The first work of the team of Professor Friedberg (University
of Pennsylvania, Philadelphia, USA) has shown promising results with a median overall
survival of 31 months [63]. PDT is not only a powerful technique to destroy human cells but
also for viruses [64], yeasts [65], molds [66], bacteria [67], protozoa [68], parasites [69], and
insects (Section 3.2). PDT is used in the development of new strategies to treat malaria and
more generally to treat tropical diseases, either by controlling the propagation vector of the
disease (Section 3.2), by inactivation of microorganisms responsible for these diseases, or by
inactivating parasites (Section 3.3).
3.2. Prevention: destruction of mosquito larvae
3.2.1. Generalities
More than 700 million people are affected annually by mosquitoes in Asia, Mexico, Central
America, South America, and Africa. A promising strategy to control diseases transmitted by
mosquitoes (malaria, filarial, and dengue fever) is the control of these vectors. Mosquitoes are
vectors of pathogens: Aedes is responsible for dengue fever, yellow fever, and encephalitis;
Anopheles for malaria and encephalitis; and Culex for yellow fever and encephalitis [70].
Pesticides such as DDT (dichlorodiphenyltrichloroethane) have been used in affected area
leading to decline of the mosquito population. Nevertheless, the use of these pesticides induces
risks for safety reasons, development of resistance in major vectors, environmental and human
health problems, etc. There is a need for developing improved insecticide, and the use of light
with a PS is a possibility. In this case, the PS is called a photopesticide. One of the first re-
searchers who described the potential of photosensitive molecules as insecticides was probably
A. Barbieri in 1928 [71]. In 1979, rose bengal was used to treat Culex larvae [72]. In 1983, a
review was written by J. Robinson about the photosensitizing dyes used as insect control agent
[73]. The concept is to make a gulp down a small amount of PS to a mosquito larva, and then,
Current Topics in Malaria212
after PS excitation by sunlight, the larva dies. Reviews have been published recently on this
topic [70, 74]. The use of porphyrins has been described from the late 1980s [75, 76]. Different
porphyrin derivatives have been then tested such as chlorophyllin, pheophorbide, and
hematoporphyrin in laboratory conditions but also in semi-field conditions. A synthetic meso-
substitute developed by Lucantoni et al. in 2012 had a potent photosensitizing activity on Aedes
aegypti larvae that are responsible for the dengue in laboratory conditions [77].
3.2.2. Anopheles mosquitoes: the primary vector for malaria
Malaria is spread to humans by the bite of the female anopheles mosquito. In 2012, Fabris et
al. described the photolarvicidal activity of a new PS called C12-porphyrin (5-(4-N-dodecyl-
pyridyl)-10,15,20-tri(4-N-methylpyridyl)-21H,23H-porphyrin tetraiodide) [78]. This molecule
was first supplied by Frontier Scientific Inc. (US Patent no. 6 573 258), and our team improved
the synthesis and performed the photophysical properties study [79]. The structure of molecule
is presented in Figure 5.
Figure 5. Chemical structure of C12-porphyrin.
In collaboration with the Institut de Recherche en Sciences de la Santé (IRSS) located in Burkina
Faso, Fabris et al. studied the potential of C12-porphyrin as a photolarvicide for the control of
Anopheles. Two different formulations with C12 were prepared: one is composed of Eudragit
S100, an anionic methacrylic acid/methyl methacrylate copolymer, and the other is a fraction
of cat food pellets. Both of them proved to be very efficient in laboratory conditions. The
porphyrin-mediated photoinactivation of anopheles larvae could represent an interesting
approach in the achievement of reduction of malaria morbidity and mortality.
3.3. Prevention: photoinactivation of parasites in blood
3.3.1. Generalities
With the emergence of many antibiotics, PDT declined for the treatment of parasite-related
diseases, and it is only in recent decades that it knew a regain of interest with the increasing
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problem of antibiotic resistance [80]. Antibiotic resistance is a global problem that reduces the
power of conventional treatments of many diseases (both nosocomial and community-
acquired infections). It concerns all pathogens including bacteria, fungi, and viruses.
To circumvent this bio-resistance, an attractive approach is PDT as non-antibiotic strategy to
inactivate microorganisms (bacteria, viruses, parasites, etc.). This process is called antimicro-
bial photodynamic therapy (aPDT) [81, 82] or antibacterial PDT [83, 84] but is also known as
photodynamic inactivation (PDI) [85–87] or photodynamic antimicrobial chemotherapy
(PACT) [88–91]. This treatment can be effective in the case of chronic ulcers, infected burns,
acne vulgaris, and a variety of local bacterial infections but also in the case of periodontitis [92],
dengue [93], tuberculosis [94], viral infection [95], and malaria [96–99]. A very large variety of
microorganisms have been studied and are listed by Alves et al. in a recent review [70] in which
the insect pest elimination, water disinfection, and elimination of food-borne pathogens are
described. A state of the art of PDT (potential) applications in animal models and clinical
infectious diseases has been submitted by Dai et al. in 2009 [95], and numerous PSs are
described [99, 100].
3.3.2. Inactivation of P. falciparum in human RBCs
Malaria is no more considered as poverty-related disease in Western countries, and attention
has been paid to developing blood decontamination methods, vaccines, or new therapies. The
spread of malaria disease, particularly with P. falciparum, in high-risk countries by blood
transfusion is very worrying, especially as global traveling is continuously increasing.
Inhabitants of tropical and subtropical regions where malaria is endemic can develop an
immune response. However, they can carry a significant amount of parasites that can be
transmitted by transfusion even if the blood is frozen (3 weeks’ survival) [101, 102]. Decon-
tamination of blood can be carried out according to several protocols including solvent-
detergent methods, filtration, deleucocytation, photochemical techniques, etc. PSs such as
psoralens, porphyrins, acridines, phenothiazines, porphyrins, and others can be used as
additive for blood sterilization, and numerous protocols have been described, some of them
could be found in [103, 104].
The life cycle of Plasmodium can be characterized by two phases: (a) the asexual proliferative
phase in humans (intermediate host), called schizogony. This phase takes place in two different
locations in humans and chronologically first within hepatocytes in the liver (exoerythrocytic
cycle) and in circulating erythrocytes (RBC cycle). It also stands in the mosquito as a result of
the sexual phase, (b) a sexual differentiation phase followed by asexual reproduction, called
sporogony, which begins in humans and continues in the mosquito by the maturation of these
in male and female gametes. As already mentioned, in erythrocytes, P. falciparum ingests 30–
80% of hemoglobin, which is then digested in the food vacuole (an acidic organelle) and
detoxified into hemozoin. This hemozoin itself could be a PS for killing P. falciparum, and
Leblanc et al. [105] demonstrated that a simple irradiation of infected cultured RBCs by a near
IR laser (800 nm) could induce a ~0.5 log reduction in parasitemia, but this is not enough for
decontamination of blood.
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Historically, Ehrlich’s group was the first to use methylene blue (Figure 6) as a PS [106] and
Rounds et al. conducted a pioneering work on the photokilling potency of a ruby laser and
methylene blue on cells infected by P. lophurae [107]. Since then, a wide variety of dyes have
been explored. Merocyanine 540 was one of the first PSs used for the decontamination of blood
[108] which reduced the concentration of parasites by 3 log when exposed to light. However,
the overlapping between hemoglobin and the PS absorption made it not suitable for depara-
sitization.
Figure 6. PS used for blood decontamination.
Riboflavin or vitamin B2 (Figure 6) deficiency is closely related to malaria [109, 110], and its
administration can prevent hemozoin formation in the asexual cycle in the food vacuole of
erythrocytes. Akompong et al. observed that addition of riboflavin can induce a 65% decrease
of the food vacuole volume and subsequently damage to light-exposed contaminated blood
[111]. In 2013, Goodrich’s group tested the “Mirasol® pathogen reduction technology” (PRT)
system against P. falciparum and P. yoelii [112]. This PRT system uses riboflavin and UV light
for the destruction of a broad range of blood-borne pathogens and receives the European
Community mark for both platelet and plasma applications. For P. falciparum, the percentage
of parasitemia was 0.97 and <0.0005% before and after treatment, respectively. Similar results
were obtained in vivo with blood of mice infected by P. yoelii. Recently, the “International
Society for Medical Laser Applications” ordered a clinical trial named “Antimicrobial photo-
dynamic therapy as a new treatment option for Malaria” in India on a group of 50 patients
receiving an antimicrobial photodynamic treatment (riboflavin + 447 nm blue laser) over a
period of 5 days plus conventional treatments [113].
In a recent research, Sigala et al. [114] demonstrated that sequencing of P. falciparum genome
and some gene deletions did not affect the heme formation indicating that the host enzymes
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are involved and can be a parallel pathway for the life cycle of P. falciparum. They showed the
involvement of protoporphyrin IX (PPIX; Figure 6) in this parallel pathway and proposed a
new treatment based on the chemoluminescence of luminol and aminolevulinic acid (ALA;
Figure 6), which is the initial building block of PPIX [115] to produce ROS. The combination
of ALA, luminol, and stimulating factor (4-iodophenol or dihydroartemisinin) decreased the
parasitemia in the range of 75–80% [114]. ALA has also been described by Smith and Kain as
a potentiate PS for killing P. falciparum in the presence of white light. The culture incubated by
0.2 mM ALA for 8 hours and exposed to light for 30 min exhibited a parasitemia less than
0.002% after 2 days [116].
PS Conditions Effects Reference
Hemozoin 800 nm; 485 mW/cm2; 60 min ~0.5 log reduction in parasitemia [105]
Methylene blue 694 nm; 70 J/cm2 Preferential uptake by infected
erythrocytes by imaging
[107]
Merocyanine 540 485 nm; 26 W/m2; 30 min 1000-fold reduction in parasitemia [108]
Riboflavin No irradiation /48h 65% decrease in food vacuole volume [111]
Riboflavin UV ; 6.24 J/mL ; 72 h <0.002% survival [112]
ALA White light;





SnPPIX No irradiation IC50 = 6.5 μM (85 μM for chloroquine)
on trophozoite lysate
[118]
Zn-PPIX No irradiation IC50 = 330 nM on RBC [119]
Diarylporphyrin No irradiation IC50 = 20 nM on erythrocytes [120]
Pheophorbide
Ph4-OH
660 nm; 7 W/cm2; 20 min Total eradication with 2 μM/L [121]
PC4 phthalocyanine >600 nm; 60 J/cm2; 10 min <0.025% survival with 2 μM/L [122]
Table 1. Bibliographic data.
In 1996, Martiney et al. [117] described a slight inhibition of hemozoin formation by using Zn-
PPIX without light. Using trophozoite lysate of P. falciparum, Begum et al. obtained similar
results with SnPPIX with an IC50 = 6.5 μM (to be compared to 85 μM for chloroquine) [118].
Recently, Garcia’s group [119] encapsulated metal-PPIX (2H, Fe, Co, Cu, Mn, Ni, and Zn) in
marine atelocollagen using the coacervation technique. They obtained an IC50 = 330 nM (for
Zn-PPIX) on RBC and found that encapsulated Zn-PPIX was 80-fold more effective than the
nonencapsulated Zn-PPIX and similar to chloroquine. In 2013, Abada et al. evaluated a series
of 11 diversely substituted porphyrins against P. falciparum [120]. Only the 5,15-di-(3,4,5-
trimethoxyphenyl)-10-(5-oxopyrrolidine-2(S)-carboxylate) (Figure 6) porphyrin has an
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efficiency comparable to chloroquine with an IC50 value of 20 nM with a slight delay of infected
mice survival.
The photosensitized inactivation of P. falciparum has been investigated by Grellier et al. [121]
by using N-(4-butanol) pheophorbide derivative (Ph4-OH) as PS. Illumination at 660 nm
(7 mW cm−2) of parasitized whole blood induced a total eradication using 2 μM Ph4-OH and
20 min illumination, 4 μM Ph4-OH and 10 min illumination, or 8 μM Ph4-OH and 5 min
illumination. The blood remained uncontaminated for at least 2 weeks. These results are better
than those obtained with merocyanine 540 [108] and comparable to that obtained with
phthalocyanines. In fact, Lustigman and BenHur [122] described the phthalocyanine HOSiP-
cOSi(CH3)2(CH2)3N(CH3)2 (Pc 4) as PS for blood decontamination and obtained an inactivation
(≥99.8%) of P. falciparum clones 7G8 and HB3 by 10 and 40 min irradiation with a xenon short-
arc lamp (>600 nm). The same team evaluated an IC50 of 24 nM in the dark [123]. The main
results are summarized in Table 1 (when available).
Besides the decontamination of blood or dialysis, numerous studies have been conducted to
understand the physiology of the human malaria parasite Plasmodium, and some PSs have been
used. For example, 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-hexadecanoic
acid (BODIPY FL C16) has been used as a marker for chloroquine resistance [124] or spatial
distribution of oxidative stress in infected erythrocytes [125]. Other examples are 5,6-chloro-
methyl-2,7-dichlorodihydrofluorescein diacetate (CM-H2DCFDA), 5′,6′-carboxy-10-dimethy-
lamino-3-hydroxy-spiro[7H-benzo[c]xanthene-7,1′(3H)-isobenzofuran]-3′-one (SNARF), and
2,7-bis-(2-carboxyethyl)-5,6-carboxyfluorescein acetoxymethyl ester (BCECF) for the meas-
urement of the parasite’s food vacuolar pH [126].
4. Curative treatment: drugs inhibiting β-hematin formation
Among various strategies, we will focus in the following part only on antimalarial drugs that
inhibit the β-hematin formation by heme-drug interaction (purely π-π interactions). This
strategy of drug development uses the heme scaffold itself as a hematin crystallization
inhibitor (Figure 2). We can quote quinine, chloroquine, rufigallol and exifone and artemisinin,
which are currently used as antimalarial drugs via this strategy (Figure 7).
Figure 7. Structures of current antimalarial drugs.
Several studies and reviews [97] reported that porphyrins can inhibit the process of heme
crystallization in the acidic food vacuole of the malaria parasite. As current antimalarial drugs,
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porphyrins are able to inhibit the β-hematin formation by strong π-π stacking interactions.
Several porphyrins have been studied for their use in heme aggregation inhibition.
Figure 8. Structures of hematin, PPIX, and hematoporphyrin.
In 1997, Basilico et al. [127] evaluated the effect of two non-iron metalloporphyrins (PPIX and
hematoporphyrin) on the crystallization of α-hematin (Figure 8) to β-hematin also called
synthetic hemozoin (Figure 2). Crystallization of hematin may be achieved in 4.5 M sodium
acetate buffer at 60°C [35]. Heme and β-hematin may be differentiated by their IR spectroscopic
characteristics [128]. IR spectra of β-hematin show two bands at 1662 and 1209 cm−1, which
disappear in IR spectra of heme. From this property, Basilico et al. demonstrated that free-base
porphyrins inhibit heme crystallization with hematoporphyrin more actively than PPIX. The
presence of hydroxyl groups can explain the better inhibitory ability of hematoporphyrin.
In 1999, Tamarelli’s team also showed that Fe(III)PPIX is reduced to Fe(II)PPIX as a novel
endogenous antimalarial because Fe(II)PPIX molecules inhibit the crystallization process
causing the death of the parasite [129].
Figure 9. Structure of antimalarial drugs designed by Bhat (left) and Abada (right).
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Some researchers are interested in the synthesis of free-base porphyrins. In 2008, Bhat et al.
[130] synthesized and evaluated the antimalarial activity of a series of porphyrin thiosemicar-
bazides. Only one compound (Figure 9 left) possesses an ability to inhibit β-hematin formation
similar to chloroquine and quinine, the control drugs that are usually used in the malaria
treatment. More recently, Abada et al. [120] synthesized a new 5,15-diarylporphyrin (Figure 9
right) with a good activity against Plasmodium with 20 nM IC50 value. The in vivo evaluation
on P. berghei in mice model showed that this compound allowed delaying the death of the
animal on about two days.
Figure 10. Structure of porphyrins and phthalocyanines developed by Wright and Begum.
In 2000, Wright’s team highlighted the presence of other metal ions than Fe(III) can influence
the conversion of heme to β-hematin. A number of metallo-PPIX, including Fe(III), Cr(III),
Co(III), Cu(II), Mn(III), Mg(II), Zn(II), and Sn(IV) showed in vitro an ability to inhibit the β-
hematin formation (Figure 10) [131]. In 2003 [132], phthalocyanines, phthalocyanine tetrasul-
fonate (PcS) and Ni(II)PcS, and anionic porphyrins, meso-tetra(4-sulfonatophenyl) porphyrin
(TPPS4) and meso-tetra(4-carboxyphenyl) porphyrin (TPPC4), came to complete the previous
study (Figure 10). All of them are inhibitors of heme crystallization. Among them, Mg(II),
Zn(II), and Sn(IV) acted six times more efficiently than the free ligand PPIX and were more
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efficient than the chloroquine standard as well. These results showed that metalloporphyrins
with high oxidation state could form complexes with heme through the Fe-propionate linkages
while being efficient crystallization inhibitors.
Figure 11. Structure of cobalamin derivatives.
Figure 12. Mn(II) complexes of alkylated tetraphenylporphyrin with a fluorinated artemisinin.
The same behavior was observed by Begum et al. [118] who evaluated the antimalarial activity
of free-base PPIX, deuteroporphyrin IX (DPIX), and hematoporphyrin IX (HPIX) and their
corresponding complexes with Ga(III), Ag(III), Pd(II), Co(III), Mn(III), Sn(IV), Cr(III), and
Fe(III) ions (Figure 10). Once again, SnPPIX at 15.5 μM had a better activity than the chloro-
quine control. Both GaPPIX and GaDPIX showed an antimalarial activity also.
In the same way, Chemaly et al. [133] observed that cobalamins (cbls) also called vitamin B12
(corrin ring with a chemical structure close to the heme but the central iron atom is replaced
by an atom of cobalt) possess antimalarial activity. Methylcobalamin (CH3-cbl), adenosylco-
balamin (Ado-cbl), and aquacobalamin (H2O-cbl) (Figure 11) showed increased efficacy over
the chloroquine; cyanocobalamin (CN-cbl) was a little more efficient than chloroquine. The
in vivo evaluation of vitamin B12 derivatives on the growth of P. falciparum (Ado-cbl > CH3-
cbl > H2O-cbl > CN-cbl) was slightly lower than chloroquine or quinine.
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Rodriguez et al. [134] showed that Mn(II) complexes of alkylated tetraphenylporphyrin with
a fluorinated artemisinin derivative (Figure 12) were effective inhibitors of β-hematin forma-
tion with an IC50 of 2.6 nM.
Benoit-Vical et al. [135, 136] showed a similar behavior with anionic metalloporphyrins. Alone
the meso-tetrakis(4-sulfonatophenyl)porphyrin (TPPS) and meso-tetrakis(3,5-disulfonatomesi-
tyl)porphyrin (TMPS) complexed to manganese (Figure 13) inhibited slightly the β-hematin
formation. However, the fact of combining them with β-artemether enhanced strongly the in
vitro and in vivo antimalarial activity of β-artemether.
Figure 13. Structure of MnTPPS, MnTMPS, and other antimalarial derivatives.
5. Conclusion and perspectives
Malaria eradication is one of the great issues for humankind in the decades ahead. Based on
figures from the World Malaria Report 2015, today more than ever, we are on the right track to
reach this objective. The decline in cases and deaths caused by malaria stems from the relentless
efforts of researchers to understand how the P. falciparum affects the RBCs. These different
studies generated a wide range of strategies to prevent and treat malaria. Transfusion-
transmitted malaria (TTM) must be understood as a high-risk situation, not only in African
countries at risk but also around the world due to the increased immigration and travel from
malaria-endemic areas. As mentioned in Section 3.3.2, malaria parasites can be transmitted by
transfusion even if the blood is frozen (3 weeks’ survival). In Europe, for example, all donated
bloods are subjected to a large number of safety procedures including nucleic acid testing,
blood filtration, or bacterial culture, but these are not done in many developing countries
because of limited funds. All blood products are currently available in sterilized forms, except
red blood cell (RBC) and platelet concentrates (PCs). The treatment of whole blood with a
photosensitizer and light is a promising strategy. Very recent studies showed that this treat-
ment can be achieved by riboflavin plus irradiation [137] and does not alter the quality of the
blood [138]. As we already mentioned in Section 3.3.2, a first clinical study worldwide
employing antimicrobial PDT is under progress in India using riboflavin as a photosensitizer
and 447 nm blue laser. This chapter report focuses on innovative approaches using PDT or the
design of new antimalarial drugs that is able to inhibit the β-hematin formation via heme-drug
interaction.
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